Biovest International, based in Minneapolis, MN, focuses on developing high-density cell fiber bioreactor systems and personalized immunotherapies. The company offers products like BiovaxID (dasiprotimut-T) and services in autologous active immunotherapy, particularly targeting cancer vaccines. With a mission to advance biomedicine, Biovest aims to improve treatment outcomes for conditions such as B-cell non-Hodgkin’s lymphoma.
Biovest International has achieved significant milestones, including the development and clinical evaluation of BiovaxID™, a personalized cancer vaccine. The company emerged from Accentia Biopharmaceuticals in the late 1990s and has since been at the forefront of commercializing personalized immunotherapies. Under the leadership of Dr. Rebecca Thompson, Biovest continues to impact the biomedicine industry with innovative solutions and a dedicated team of 50 employees.
